Back
Sarepta Therapeutics, Inc. (SRPT)
BiotechnologySRPT · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$20.52
+1.53%Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for education and research only — not financial advice.
Key metrics
EPS
$-7.13
ROE
4.9%
Gross margin
21.6%
Debt/Equity
0.70x
Revenue growth
-1.9%
Sarepta Therapeutics, Inc. — company intelligence
Earnings surprises
Q1 2026$2.88 vs $1.01 est+184.7%
Q4 2025$-3.93 vs $-1.26 est-213.0%
Q3 2025$-0.01 vs $-0.83 est+98.8%
Q2 2025$1.89 vs $0.77 est+146.8%
Analyst consensus · 33 analysts
13 Buy15 Hold5 Sell
Updated Jul 4, 2026
Insider activity · 90 days
8 buys0 sellsnet +135,000 shares
Barry RichardBuy 16,875 · Jun 4, 2026
BEHRENS M KATHLEENBuy 16,875 · Jun 4, 2026
Boor Kathryn JeanBuy 16,875 · Jun 4, 2026
Recent SEC filings
4 — Insider transaction reportJun 5, 2026
4 — Insider transaction reportJun 5, 2026
4 — Insider transaction reportJun 5, 2026
Latest news
Piper Sandler Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20 — Benzinga · 1d ago
Wolfe Research Upgrades Sarepta Therapeutics to Outperform, Announces $27 Price Target — Benzinga · 2d ago
Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs — Benzinga · 1w ago
Sarepta Therapeutics Says FDA Accept sNDAs For AMONDYS 45 And VYONDYS 53 For Treatment Of Duchenne Muscular Dystrophy; PDUFA Target Action Data February 28, 2027 — Benzinga · 1w ago
Sarepta: Caution Still Warranted Despite FDA's Gene Therapy-Friendly Stance — SeekingAlpha · 3w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
About Sarepta Therapeutics, Inc.
Weekly undervalued picks (like SRPT)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.